Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-07
2011-06-07
Moore, Susanna (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S281000, C544S263000
Reexamination Certificate
active
07956061
ABSTRACT:
The present invention is directed to novel substituted bicyclic pyrimidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
REFERENCES:
patent: 2006/0178377 (2006-08-01), Meng et al.
patent: 2004/032836 (2004-04-01), None
patent: 2004/032836 (2004-04-01), None
Abu Elmaai, T. M. et al., “Routes to Pyrazolo[3,4-e][1,4]thiazepine, Pyrazolo[1,5-a]pyrimidine and Pyrazole Derivatives” Journal of the Chinese Chemical Society, vol. 50, pp. 413-418, 2003.
Green, B. D. et al., “Inhibition of dipeptidyl peptidase IV activity as a therapy of Type 2 diabetes” Expert Opin. Emerging Drugs, vol. 11, No. 3, pp. 525-539, 2006.
Stonehouse, A. H. et al., “Management of Type 2 diabetes: the role of incretin mimetics” Expert Opin. Pharmacother, vol. 7, No. 15, pp. 2095-2105, 2006.
Combettes, M, MJ., “GLP-1 and type 2 diabetes: physiology and new clinical advances” Current Opinion in Pharmacology, vol. 6, pp. 598-605, 2006.
Holst, J. J. et al., “New Horizons in Diabetes Therapy” Immun., Endoc. & Metab. Agents in Med. Chem, vol. 7, pp. 49-55, 2007.
Campbell, R. K., “Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus” The Annals of Pharmacotherapy, vol. 41, pp. 51-60, 2007.
Ashton Wallace T.
Caldwell Charles G.
Dong Hong
Gao Ying-Duo
Scapin Giovanna
Fair Janet E.
Merck Sharp & Dohme Corp.
Moore Susanna
Todaro John C.
LandOfFree
Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2654301